Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
about
CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradationThe selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein AlfyHDAC6 and microtubules are required for autophagic degradation of aggregated huntingtinClioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1The role of ALFY in selective autophagyCell biology of spinocerebellar ataxiaMouse models of polyglutamine diseases: review and data table. Part IThe unstable repeats--three evolving faces of neurological diseaseSilencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic miceModulation, Plasticity and Pathophysiology of the Parallel Fiber-Purkinje Cell Synapse.The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7Metabotropic glutamate receptors: from the workbench to the bedside.SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776.Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome.Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1.Oligonucleotide-based strategies to combat polyglutamine diseases.Phosphorylation of NBR1 by GSK3 modulates protein aggregation.Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1Mutant β-III spectrin causes mGluR1α mislocalization and functional deficits in a mouse model of spinocerebellar ataxia type 5.Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation.The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solutionNeurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status.RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1Development of targeted therapies for Parkinson's disease and related synucleinopathiesTetracycline inducible gene manipulation in serotonergic neurons.Neurogenetics: advancing the "next-generation" of brain research.ETS1 regulates the expression of ATXN2.Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapyUbiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection.Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6Viral-based modelling and correction of neurodegenerative diseases by RNA interference.Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder.Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model.Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology.Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model.
P2860
Q24296740-CF94D824-7A99-404D-BEBC-83ED823B7894Q24307759-F0536517-A4E7-4827-B145-1C6CBED6C1EEQ24337155-9273FD17-A6BB-4B45-9E37-C35A006FBEABQ24535603-2B93ECE5-AA70-4CB5-A134-4DCBDDAE6F10Q24655547-2E70E018-AFF3-47C3-89BA-98E814215C23Q26828736-BB279CBD-0647-41E7-8443-D0035E1A2810Q26829511-3D9C299F-B31C-4ACC-953F-699292556790Q26853025-76989706-BDDB-40DB-AE78-E7090CDE2F50Q27025923-16364C51-339B-41C3-96F6-DA5CA350A78CQ27324749-09AA7637-3672-4D93-9EA0-F9C30D59E03AQ28069538-180F0987-18B8-4B9D-AF54-4DCCE0960C5FQ28505609-5EFB6418-7215-42CD-A4D7-6CFD621B18B1Q30448778-60E42B18-052B-4590-B4A6-7C94DE138B36Q30496777-9598CC94-F1C4-435D-B142-BAC0ED26F2C6Q30573147-5827A5FF-3FB3-4539-9FC0-A7A44A2A06A5Q33607305-C9C62009-0367-43C1-8933-A5E929486FF0Q33649463-874F3251-2A73-4A23-920D-718BCDF14786Q33758282-01A2D1FD-DCB1-4FFF-934B-BD6A261E032AQ33791247-A7841F41-B6AC-4F8E-90A1-899EFE7D2897Q33878926-96250025-B908-45A9-9950-4816EE571BBBQ33889363-069461BB-9F52-470C-B3DE-CA3B3F61CE11Q33935986-11C11774-0F26-4A95-B69D-57DA17E97C33Q33947993-62A24968-6712-484D-8118-1D631129285FQ33980214-9C646289-0B35-4E48-A64E-2F05DC954392Q34046625-B6EB6C1F-A6E6-4734-B034-0200FAD1B324Q34235172-500F29EB-3E90-45E5-90B5-98813DB47651Q34238616-60ED5328-6028-48DA-9803-EB4AD88E7346Q34302418-62BA8AE6-85BD-4CFE-9176-89F3418FE07EQ34315505-1198F97D-E610-4B86-BBE5-92159561134AQ34390181-CA4C0253-4BD5-478F-B442-0463F874E7FEQ34397572-9C65B477-4D15-41B6-BBF0-5042E22633E8Q34412364-7D4EDC4A-AB7E-4E09-847C-C122D3EF3B04Q34456340-2F88E34F-C0DD-4848-8C59-97AF34EAEEA7Q34471754-1AB41A75-C039-4CBE-9265-94F5BF8F2DDBQ34498957-4BF0F5C0-3C58-4AAF-9E1C-DB30DEE794B0Q34766860-A2FEBD71-FA08-4D01-87CF-CD765B55FC1DQ34797845-BFB49B7A-00BB-4B7E-A958-22FBB6EC6184Q34955481-A5EB381A-F63F-4D8B-8C57-31AC3C6EFF82Q35070164-78337D3D-98B1-4855-856B-9636791244DDQ35184199-B615A87B-4C18-4517-BF0C-946FF13541BF
P2860
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@en
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@nl
type
label
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@en
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@nl
prefLabel
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@en
Recovery from polyglutamine-in ...... ditional SCA1 transgenic mice.
@nl
P2093
P1476
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice
@en
P2093
H Brent Clark
Lisa A Duvick
Michael D Kaytor
Michael S Berlinger
P304
P356
10.1523/JNEUROSCI.2978-04.2004
P407
P577
2004-10-01T00:00:00Z